Vincristine sulfate

Plasma Cell Myeloma

Roswell Park Cancer InstituteSmall moleculePhase 3Dormant

BBB

74/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 66/ 100
Competitive Position: 89/ 100

Competitive context

475 Active assets in the Plasma Cell Myeloma cohort.

Asset / Sponsor	Phase	Rating
Hyaluronidase fihj Massachusetts General Hospital	Phase 4	BBB
Filanesib PETHEMA Foundation	Phase 2	BBB
Cyclosporin A Seoul National University Hospital	Phase 3	BBB
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT University of Birmingham	Phase 4	BBB
Epoetin Alfa Mayo Clinic	Phase 3	BB

View all 50 →

Same molecule, other indications

Vincristine sulfate is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant

A

Indicative · Phase 3

81 / 100

diffuse large B-cell lymphomaActive

A

Indicative · Phase 2/3

80 / 100

childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.